Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 1
2003 3
2004 4
2005 1
2006 1
2007 3
2008 3
2009 3
2010 1
2011 1
2012 1
2014 1
2015 1
2017 1
2018 1
2019 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; German HCV Resistance Study Group; University Hospitals; Academic Hospitals; Local study sites (private practices), Germany. Dietz J, et al. J Hepatol. 2023 Jan;78(1):57-66. doi: 10.1016/j.jhep.2022.08.016. Epub 2022 Aug 27. J Hepatol. 2023. PMID: 36031158
Serum and bile markers for cholangiocarcinoma.
Nehls O, Gregor M, Klump B. Nehls O, et al. Semin Liver Dis. 2004 May;24(2):139-54. doi: 10.1055/s-2004-828891. Semin Liver Dis. 2004. PMID: 15192787 Review.
Sarcoidosis mimicking cholangiocarcinoma.
Nehls O, Hass HG, Weber P, Dette S, Lauer UM, Schlemmer HP, Oehlert M, Gregor M, Klump B. Nehls O, et al. Endoscopy. 2006;38 Suppl 2:E65-6. doi: 10.1055/s-2006-944890. Endoscopy. 2006. PMID: 17366421 No abstract available.
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.
Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer KH, Berger A, Matschenz K, Buggisch P, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. Clin Gastroenterol Hepatol. 2021 Jan;19(1):195-198.e2. doi: 10.1016/j.cgh.2019.10.051. Epub 2019 Nov 6. Clin Gastroenterol Hepatol. 2021. PMID: 31706062 Free article.
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13. Gastroenterology. 2018. PMID: 29146520
Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial.
Dollinger MM, Lautenschlaeger C, Lesske J, Tannapfel A, Wagner AD, Schoppmeyer K, Nehls O, Welker MW, Wiest R, Fleig WE; AIO Hepatobiliary Study Group. Dollinger MM, et al. Among authors: nehls o. BMC Cancer. 2010 Aug 24;10:457. doi: 10.1186/1471-2407-10-457. BMC Cancer. 2010. PMID: 20735834 Free PMC article. Clinical Trial.
27 results